Clinical Trials Logo

Filter by:
NCT ID: NCT05063994 Completed - Clinical trials for Congenital Adrenal Hyperplasia

Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia

CONnECT
Start date: December 13, 2021
Phase: Phase 3
Study type: Interventional

This study is a randomized, double-blind, active-controlled, phase III study of Chronocort® compared with immediate-release hydrocortisone replacement therapy in participants aged 16 years and over with Congenital Adrenal Hyperplasia.

NCT ID: NCT05063786 Active, not recruiting - Clinical trials for Advanced Breast Cancer

Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)

ALPHABET
Start date: September 14, 2021
Phase: Phase 3
Study type: Interventional

Randomized phase III trial of trastuzumab + Alpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously treated HER2+ Advanced Breast cancer.

NCT ID: NCT05063565 Recruiting - Clinical trials for Hepatocellular Carcinoma

TheraSphere With Durvalumab and Tremelimumab for HCC

ROWAN
Start date: November 3, 2023
Phase: Phase 2
Study type: Interventional

The objective of the ROWAN clinical study is to assess the efficacy of local tumor control in HCC patients who receive TheraSphere followed by durvalumab and tremelimumab.

NCT ID: NCT05063513 Withdrawn - Clinical trials for REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS

Autologous Stem Cell Transplantation: International Lupus Trial

ASTIL
Start date: July 2009
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate remission induction therapy for refractory Lupus Erythematosus with autologous hematopoietic stem cell transplantation (AHSCT) versus Rituximab (anti CD20) followed by maintenance therapy with mycophenolate mofetil (MMF).

NCT ID: NCT05063162 Recruiting - Clinical trials for Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)

cosMOG
Start date: February 2, 2022
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD).

NCT ID: NCT05063110 Recruiting - Clinical trials for Adults Patients Having Non Severe HLH

Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIB

HLH-JAK
Start date: May 1, 2022
Phase: Phase 2
Study type: Interventional

This project aims to test the effectiveness of ITACITINIB in sporadic Hemophagocytosis Lymphohistiocytosis (HLHs)

NCT ID: NCT05063097 Active, not recruiting - Clinical trials for Substance-Related Disorders

Addiction in Intensive Cardiac Care Units

ADDICT-CCU
Start date: April 6, 2021
Phase:
Study type: Observational

Background: Illicit drug use is a growing issue in Europe and leading cause of acute cardiac events in patients admitted to intensive cardiac care units. Indeed, cardiovascular complications are one of the main causes of death due to illicit drug use. However, its prevalence in patients hospitalized in intensive cardiac care units is unknown. Objectives: This large multicenter prospective study will assess the prevalence of illicit drug use in consecutive patients hospitalized in intensive cardiac care units by urine drug assay. Eligibility: - Patient over 18 years old admitted to intensive Cardiac Care Unit (CCU) for any reason. - Without hospitalization for a planned interventional procedure. - Without hospitalization for more than 24 hours at any hospital facility before admission to the CCU. Design: - Multicentre cohort study with a prospective enrolment of all consecutive patients admitted to the CCU to assess the prevalence of illicit drug use in 40 centers throughout France. - Participants will be screened with a physical exam, medical history and addiction survey. - Participants will be screened for drug use by urine drug assay (NarcoCheck®, Kappa City Biotech SAS, Montluçon, France) and for tobacco by standardized exhaled carbon monoxide (CO) measurement with a CO-Check Pro device (Bedfont Scientific Ltd, Kent, UK). - Participants will be followed at 6 months of follow-up to assess the occurrence of cardiovascular events.

NCT ID: NCT05063084 Recruiting - Pediatric Surgery Clinical Trials

High-flow Nasal Cannula Oxygenation During Rapid Sequence Induction in Children

OPTINECK
Start date: February 9, 2023
Phase: Phase 3
Study type: Interventional

This randomised study aims to compare the utilization of high-flow humidified nasal oxygenation (HFNO) with standard care, using apnoeic facemask oxygenation, during rapid sequence induction (RSI) of anesthesia in young children. 170 children aged less then 11 years, admitted to the operating room for surgery and with a medical indication of a RSI of anesthesia will be recruited in one university hospital (Necker-Enfants-Malades in Paris). Children will be randomly assigned into two groups: the control group will benefit of standard care and the HFNO group will receive heated and humidified oxygen through a nasal cannula device during pre-oxygenation and apnoea time prior to tracheal intubation. HFNO has been evaluated and showed benefits in rapid sequence induction of anesthesia in adults and prolonged apnea time before desaturation in children. To the investigators' knowledge the potential benefit of HFNO during RSI in young children remain to be evaluated.

NCT ID: NCT05062668 Recruiting - POAG Clinical Trials

Efficacy and Safety of iStent Inject and Inject W in the Management of Primary Open-angle Glaucoma

EII
Start date: October 8, 2021
Phase:
Study type: Observational

Primary open-angle glaucoma (POAG) is a chronic eye disease in which the only validated treatment is to lower intraocular pressure (IOP). It is the 2nd leading cause of blindness worldwide. The iStent® inject and inject W is an implantable device that is part of a new entity of so-called minimally invasive glaucoma surgery whose goal is to lower IOP with minimal tissue disruption in order to avoid the complications of conventional glaucoma surgery. This surgery is used in conjunction with cataract surgery in France. The primary objective is to study the 1-year efficacy and safety of combined cataract and iStent inject and inject W in the management of POAG in an observational, retrospective, controlled study of a cohort of POAG patients undergoing cataract surgery only.

NCT ID: NCT05062655 Recruiting - Clinical trials for Hospitalized Patient

Interest of Drug Reconciliation to Ensure the Continuity of the Treatment at Discharge

ICOCON
Start date: August 3, 2021
Phase: N/A
Study type: Interventional

From a regulatory point of view, medication reconciliation is a necessary process to ensure safe medication management for patients. According to national studies and the international scientific literature, the information received by patients and health professionals at discharge from hospital is insufficient. Medication reconciliation at discharge reduces medication errors and rehospitalisation, but few studies have been conducted on the impact of a coordinated and reliable care pathway on medication continuity. The iCoCon study will enable a new healthcare organisation to be set up in order to improve the quality of the patient pathway and the patient's medication management. This new organisation is part of the policy of continuous improvement of the quality and safety of care